TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis
USA - NYSE:TEVA - US8816242098 - ADR
19.55 USD
+0.6 (+3.17%)
TEVA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While TEVA is still in line with the averages on profitability rating, there are concerns on its financial health. TEVA is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
TEVA had positive earnings in the past year.
In the past year TEVA had a positive cash flow from operations.
In the past 5 years TEVA reported 4 times negative net income.
TEVA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
TEVA has a Return On Assets of -0.39%. This is in the better half of the industry: TEVA outperforms 79.17% of its industry peers.
With a decent Return On Equity value of -2.31%, TEVA is doing good in the industry, outperforming 79.17% of the companies in the same industry.
TEVA has a Return On Invested Capital of 10.49%. This is amongst the best in the industry. TEVA outperforms 88.54% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for TEVA is significantly below the industry average of 15.45%.
The last Return On Invested Capital (10.49%) for TEVA is above the 3 year average (9.12%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.39% | ||
| ROE | -2.31% | ||
| ROIC | 10.49% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
1.3 Margins
With an excellent Operating Margin value of 22.59%, TEVA belongs to the best of the industry, outperforming 89.58% of the companies in the same industry.
TEVA's Operating Margin has improved in the last couple of years.
TEVA has a Gross Margin of 50.88%. This is in the better half of the industry: TEVA outperforms 64.58% of its industry peers.
In the last couple of years the Gross Margin of TEVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.59% | ||
| PM (TTM) | N/A | ||
| GM | 50.88% |
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TEVA is creating some value.
The number of shares outstanding for TEVA has been increased compared to 1 year ago.
Compared to 5 years ago, TEVA has more shares outstanding
The debt/assets ratio for TEVA has been reduced compared to a year ago.
2.2 Solvency
TEVA has an Altman-Z score of 0.63. This is a bad value and indicates that TEVA is not financially healthy and even has some risk of bankruptcy.
TEVA has a Altman-Z score (0.63) which is in line with its industry peers.
The Debt to FCF ratio of TEVA is 19.36, which is on the high side as it means it would take TEVA, 19.36 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 19.36, TEVA is in the better half of the industry, outperforming 76.04% of the companies in the same industry.
A Debt/Equity ratio of 2.46 is on the high side and indicates that TEVA has dependencies on debt financing.
The Debt to Equity ratio of TEVA (2.46) is worse than 78.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 19.36 | ||
| Altman-Z | 0.63 |
ROIC/WACC1.3
WACC8.04%
2.3 Liquidity
A Current Ratio of 1.06 indicates that TEVA should not have too much problems paying its short term obligations.
TEVA has a Current ratio of 1.06. This is amonst the worse of the industry: TEVA underperforms 80.21% of its industry peers.
TEVA has a Quick Ratio of 1.06. This is a bad value and indicates that TEVA is not financially healthy enough and could expect problems in meeting its short term obligations.
TEVA has a worse Quick ratio (0.77) than 82.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
The earnings per share for TEVA have decreased by -4.09% in the last year.
TEVA shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.18% yearly.
Looking at the last year, TEVA shows a small growth in Revenue. The Revenue has grown by 2.07% in the last year.
TEVA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.41% yearly.
EPS 1Y (TTM)-4.09%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%8.2%
Revenue 1Y (TTM)2.07%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%0.29%
3.2 Future
TEVA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.98% yearly.
Based on estimates for the next years, TEVA will show a small growth in Revenue. The Revenue will grow by 1.96% on average per year.
EPS Next Y5.48%
EPS Next 2Y4.97%
EPS Next 3Y6.98%
EPS Next 5YN/A
Revenue Next Year3.05%
Revenue Next 2Y1.85%
Revenue Next 3Y1.96%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TEVA is valuated cheaply with a Price/Earnings ratio of 7.49.
93.75% of the companies in the same industry are more expensive than TEVA, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.89, TEVA is valued rather cheaply.
The Price/Forward Earnings ratio is 7.04, which indicates a rather cheap valuation of TEVA.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 92.19% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of TEVA to the average of the S&P500 Index (22.99), we can say TEVA is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.49 | ||
| Fwd PE | 7.04 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 91.67% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 82.81% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.2 | ||
| EV/EBITDA | 7.7 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of TEVA may justify a higher PE ratio.
PEG (NY)1.37
PEG (5Y)N/A
EPS Next 2Y4.97%
EPS Next 3Y6.98%
5. Dividend
5.1 Amount
TEVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:TEVA (10/27/2025, 12:39:06 PM)
19.55
+0.6 (+3.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners12.48%
Inst Owner Change-0.54%
Ins Owners0.43%
Ins Owner Change-3.97%
Market Cap22.43B
Revenue(TTM)16.63B
Net Income(TTM)-158000000
Analysts42.22
Price Target0.05 (-99.74%)
Short Float %4.21%
Short Ratio4.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.24%
Min EPS beat(2)4.65%
Max EPS beat(2)5.84%
EPS beat(4)4
Avg EPS beat(4)3.88%
Min EPS beat(4)2.01%
Max EPS beat(4)5.84%
EPS beat(8)6
Avg EPS beat(8)4.79%
EPS beat(12)7
Avg EPS beat(12)-0.36%
EPS beat(16)9
Avg EPS beat(16)-0.6%
Revenue beat(2)0
Avg Revenue beat(2)-4.72%
Min Revenue beat(2)-4.77%
Max Revenue beat(2)-4.68%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)2.63%
Revenue beat(8)5
Avg Revenue beat(8)0.64%
Revenue beat(12)6
Avg Revenue beat(12)-0.39%
Revenue beat(16)6
Avg Revenue beat(16)-1.7%
PT rev (1m)-4.23%
PT rev (3m)-2.62%
EPS NQ rev (1m)-1.8%
EPS NQ rev (3m)-7.96%
EPS NY rev (1m)0%
EPS NY rev (3m)2.84%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-2.36%
Revenue NY rev (1m)0.29%
Revenue NY rev (3m)-1.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.49 | ||
| Fwd PE | 7.04 | ||
| P/S | 1.35 | ||
| P/FCF | 25.2 | ||
| P/OCF | 16.13 | ||
| P/B | 3.29 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.7 |
EPS(TTM)2.61
EY13.35%
EPS(NY)2.78
Fwd EY14.2%
FCF(TTM)0.78
FCFY3.97%
OCF(TTM)1.21
OCFY6.2%
SpS14.5
BVpS5.95
TBVpS-11.56
PEG (NY)1.37
PEG (5Y)N/A
Graham Number18.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.39% | ||
| ROE | -2.31% | ||
| ROCE | 13.29% | ||
| ROIC | 10.49% | ||
| ROICexc | 11.36% | ||
| ROICexgc | 49.13% | ||
| OM | 22.59% | ||
| PM (TTM) | N/A | ||
| GM | 50.88% | ||
| FCFM | 5.35% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
ROICexc(3y)10.21%
ROICexc(5y)9.09%
ROICexgc(3y)56.98%
ROICexgc(5y)49.9%
ROCE(3y)11.55%
ROCE(5y)10.49%
ROICexgc growth 3Y25.78%
ROICexgc growth 5Y17.24%
ROICexc growth 3Y15.91%
ROICexc growth 5Y18.91%
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
F-Score6
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 19.36 | ||
| Debt/EBITDA | 3.51 | ||
| Cap/Depr | 48.92% | ||
| Cap/Sales | 3.01% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 29.09% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | 0.63 |
F-Score6
WACC8.04%
ROIC/WACC1.3
Cap/Depr(3y)44.85%
Cap/Depr(5y)42.78%
Cap/Sales(3y)3.33%
Cap/Sales(5y)3.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.09%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%8.2%
EPS Next Y5.48%
EPS Next 2Y4.97%
EPS Next 3Y6.98%
EPS Next 5YN/A
Revenue 1Y (TTM)2.07%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%0.29%
Revenue Next Year3.05%
Revenue Next 2Y1.85%
Revenue Next 3Y1.96%
Revenue Next 5YN/A
EBIT growth 1Y1.19%
EBIT growth 3Y1.63%
EBIT growth 5Y5.48%
EBIT Next Year17.17%
EBIT Next 3Y7.55%
EBIT Next 5YN/A
FCF growth 1Y-24.19%
FCF growth 3Y46.96%
FCF growth 5Y27.42%
OCF growth 1Y-18.04%
OCF growth 3Y16.04%
OCF growth 5Y10.76%
TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ
What is the fundamental rating for TEVA stock?
ChartMill assigns a fundamental rating of 4 / 10 to TEVA.
What is the valuation status for TEVA stock?
ChartMill assigns a valuation rating of 8 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.
Can you provide the profitability details for TEVA PHARMACEUTICAL-SP ADR?
TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 6 / 10.
What is the valuation of TEVA PHARMACEUTICAL-SP ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 7.49 and the Price/Book (PB) ratio is 3.29.
What is the financial health of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
The financial health rating of TEVA PHARMACEUTICAL-SP ADR (TEVA) is 2 / 10.